Gelonghui, January 19丨Teyi Pharmaceutical (002728.SZ) was surveyed by a specific target on January 18, 2024, on “Will the company focus on developing proprietary Chinese medicines in the future? Proprietary Chinese medicine's revenue share?” The company replied that the company has large reserves of proprietary Chinese medicine products and that some proprietary Chinese medicine products have a large market capacity. In the context of the national industrial policy strongly supporting the development of the traditional Chinese medicine industry, the company will closely follow the major trends of national reform and development and focus on developing proprietary Chinese medicine varieties.

As of 2022, the company's proprietary Chinese medicines and chemical pharmaceutical products all accounted for about 45% of revenue, and chemical raw materials and chemical products accounted for about 10% of revenue. In 2023, as proprietary Chinese medicine products, especially the core product Special Cough Remedies, maintained good growth, and the sales share of proprietary Chinese medicine products will further increase.